Latest News and Press Releases

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment...

July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX),...

In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation   MILAN, Italy, July 11, 2025 – Italfarmaco S.p.A. announced...

June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.

Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing...

May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...

These major milestones in Q1 support advancement of Nebokitug to Phase 3 and position It to potentially become the first FDA-approved treatment for PSC.

May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP...

Yaqrit presents phase 2a data at EASL on oral HE prevention treatment; and an improved HE patient staging tool approved for use by FDA in HE phase 3